Home > Insider Trading > Filing (0001209191-16-088822)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1346830	Cara Therapeutics Inc.	CARA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1597359	Dean Slagel	C/O Esperante Bv, Siriusdreef 22 Hoofddorp P7 2132 WT		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-12-31	12,776	$17.00	1,345,562	No	4	S	Indirect	By Esperante BV
Common Stock	Disposition	2016-01-05	31,224	$17.01	1,314,338	No	4	S	Indirect	By Esperante BV

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Esperante BV
No	4	S	Indirect	By Esperante BV

Footnotes

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Esperante BV on December 17, 2015 (See Footnote 3 herein).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 - $17.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
These shares are owned by Esperante BV. The Reporting Person is a director of the Issuer and the Managing Director of Esperante BV and, as such, holds voting and/or dispositive power of the shares held by Esperante BV. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 - $17.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.